Works matching DE "GEMCITABINE"

Results: 568
    1
    2
    3
    4
    5

    Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

    Published in:
    JAMA Network Open, 2025, v. 8, n. 2, p. e2461639, doi. 10.1001/jamanetworkopen.2024.61639
    By:
    • Richters, Lisa;
    • Gluz, Oleg;
    • Weber-Lassalle, Nana;
    • Christgen, Matthias;
    • Haverkamp, Heinz;
    • Kuemmel, Sherko;
    • Kayali, Mohamad;
    • Kates, Ronald E.;
    • Grischke, Eva-Maria;
    • Altmüller, Janine;
    • Forstbauer, Helmut;
    • Thiele, Holger;
    • Braun, Michael;
    • Warm, Mathias;
    • Ossowski, Anna;
    • Wuerstlein, Rachel;
    • Ernst, Corinna;
    • Graeser, Monika;
    • Linn, Sabine C.;
    • Nitz, Ulrike
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21

    Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study.

    Published in:
    Oncology Letters, 2022, v. 24, n. 4, p. N.PAG, doi. 10.3892/ol.2022.13495
    By:
    • Tozuka, Yuichiro;
    • Ueno, Makoto;
    • Kobayashi, Satoshi;
    • Morimoto, Manabu;
    • Fukushima, Taito;
    • Sano, Yusuke;
    • Kawano, Kuniyuki;
    • Hanaoka, Akane;
    • Tezuka, Shun;
    • Asama, Hiroyuki;
    • Moriya, Satoshi;
    • Morinaga, Soichiro;
    • Ohkawa, Shinichi;
    • Maeda, Shin
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28
    29

    The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in Pancreatic Cancer Cell Lines.

    Published in:
    Nutrients, 2024, v. 16, n. 5, p. 705, doi. 10.3390/nu16050705
    By:
    • Denda, Yuki;
    • Matsuo, Yoichi;
    • Sugita, Saburo;
    • Eguchi, Yuki;
    • Nonoyama, Keisuke;
    • Murase, Hiromichi;
    • Kato, Tomokatsu;
    • Imafuji, Hiroyuki;
    • Saito, Kenta;
    • Morimoto, Mamoru;
    • Ogawa, Ryo;
    • Takahashi, Hiroki;
    • Mitsui, Akira;
    • Kimura, Masahiro;
    • Takiguchi, Shuji
    Publication type:
    Article
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39

    Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.

    Published in:
    Clinical Genitourinary Cancer, 2023, v. 21, n. 5, p. 546, doi. 10.1016/j.clgc.2023.06.012
    By:
    • Carthon, Bradley C.;
    • Se Eun Kim;
    • McDermott, David F.;
    • Dutcher, Janice P.;
    • Puligandla, Maneka;
    • Manola, Judith;
    • Pins, Michael;
    • Carducci, Michael A.;
    • Plimack, Elizabeth R.;
    • Appleman, Leonard J.;
    • MacVicar, Gary R.;
    • Kohli, Manish;
    • Kuzel, Timothy M.;
    • DiPaola, Robert S.;
    • Haas, Naomi B.
    Publication type:
    Article
    40

    Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.

    Published in:
    Clinical Genitourinary Cancer, 2022, v. 20, n. 2, p. 196.e1, doi. 10.1016/j.clgc.2021.11.006
    By:
    • Makito Miyake;
    • Takuto Shimizu;
    • Nobutaka Nishimura;
    • Keisuke Kiba;
    • Fumisato Maesaka;
    • Yuki Oda;
    • Akira Tachibana;
    • Mitsuru Tomizawa;
    • Chihiro Ohmori;
    • Yoshiaki Matsumura;
    • Kazuki Ichikawa;
    • Shinichiro Mizobuchi;
    • Takanosuke Yoshikawa;
    • Shunta Hori;
    • Yosuke Morizawa;
    • Daisuke Gotoh;
    • Yasushi Nakai;
    • Satoshi Anai;
    • Kazumasa Torimoto;
    • Katsuya Aoki
    Publication type:
    Article
    41
    42
    43

    Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).

    Published in:
    2021
    By:
    • Yamada, Daisaku;
    • Kobayashi, Shogo;
    • Takahashi, Hidenori;
    • Akita, Hirofumi;
    • Yamada, Terumasa;
    • Asaoka, Tadafumi;
    • Shimizu, Junzo;
    • Takeda, Yutaka;
    • Yokoyama, Shigekazu;
    • Tsujie, Masanori;
    • Tomokuni, Akira;
    • Tanemura, Masahiro;
    • Morimoto, Osakuni;
    • Murakami, Masahiro;
    • Kim, Yongkook;
    • Nakahira, Shin;
    • Hama, Naoki;
    • Sugimoto, Keishi;
    • Hashimoto, Kazuhiko;
    • Doki, Yuichiro
    Publication type:
    journal article
    44
    45
    46
    47
    48
    49
    50